Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery [Yahoo! Finance]
Viking Therapeutics (VKTX) VANQUISH-1 Trial Completes Early, H.C. Wainwright Retains Buy Rating [Yahoo! Finance]
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Viking Therapeutics (VKTX) Balances Rising R&D Costs With Clinical Progress: Is the Risk Worth the Potential? [Yahoo! Finance]
Viking Therapeutics (NASDAQ:VKTX) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.